Scoping Review of Targeted Ultrasound Contrast Agents in the Detection of Angiogenesis

Christopher Lau; Marielena Rivas; Jennifer Dinalo; Kevin King; Vinay Duddalwar

doi:10.1002/jum.15072

Scoping Review of Targeted Ultrasound Contrast Agents in the Detection of Angiogenesis

J Ultrasound Med. 2020 Jan;39(1):19-28. doi: 10.1002/jum.15072. Epub 2019 Jun 24.

Authors

Christopher Lau¹, Marielena Rivas¹, Jennifer Dinalo², Kevin King¹, Vinay Duddalwar¹

Affiliations

¹ Department of Radiology, Keck School of Medicine, California, Los Angeles, USA.
² Norris Medical Library, Keck School of Medicine, California, Los Angeles, USA.

PMID: 31237009
DOI: 10.1002/jum.15072

Abstract

A systematic search was conducted to categorize targeted ultrasound contrast agents (UCAs) used in cancer-related angiogenesis detection. We identified 15 unique contrast agents from 2008 to March 2018. Most primary research articles studied UCAs targeted to vascular endothelial growth factor receptor or α_v β₃ -integrin. Breast cancer and colon cancer are the most common neoplastic processes in which these agents were studied. BR55 (Bracco Research SA, Geneva, Switzerland), a vascular endothelial growth factor receptor-targeting UCA, is the first targeted UCA that has completed phase 0 trials. Our review identifies a gap in the literature regarding the application of targeted UCAs in cancer models beyond breast and colon cancers and identifies other promising UCAs.

Keywords: angiogenesis; microbubbles; targeted contrast-enhanced ultrasound.

Publication types

Review

MeSH terms

Contrast Media*
Female
Humans
Image Enhancement / methods*
Male
Neoplasms / blood supply*
Neovascularization, Pathologic / diagnostic imaging*
Ultrasonography / methods*

Substances

Contrast Media